Application of RPS3A molecule in prediction of immune cell infiltration and immune checkpoint molecular expression level in tumors and predicting model

Abstract

The invention provides an application of an RPS3A molecule in prediction of immune cell infiltration and immune checkpoint molecular expression level in tumors and a prediction model. According to theinvention, the expression level of RPS3A in postoperative tumor tissues of a hepatocellular carcinoma patient is detected; in clinical practice, the RPS3A can be used as a molecular marker to reflectthe infiltration level of immune cells in tumors and the molecular expression condition of immune checkpoints and guide the immunotherapy management of liver cancer patients, so that the immunological characteristics and prognosis risk of hepatocellular carcinoma can be evaluated, the formulation of a liver cancer individualized treatment scheme can be promoted, and relatively high guiding significance is achieved; meanwhile, the Nomogram prognosis prediction model is constructed on the basis of RPS3A molecules, compared with traditional TNM and BCLC stages, better prediction efficiency and accuracy are achieved, liver cancer patients are enabled to obtain more clinical net income, and the RPS3A molecule can be applied to clinically and accurately judging the postoperative survival time of hepatocellular carcinoma patients.

Description

technical field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of an RPS3A molecule in predicting intratumoral immune cell infiltration, expression level of immune checkpoint molecules and a prediction model. Background technique

[0002] The latest global epidemiological survey shows that hepatocellular carcinoma is the fastest growing malignant tumor among all cancers, with an annual increase of 2-3%, and its 5-year survival rate is only 18%. Although patients with early-stage hepatocellular carcinoma can receive radical surgery, the recurrence rate is still close to 50% after 2 years, and the recurrence rate is as high as 75% after 5 years. At present, the clinical judgment of postoperative recurrence and survival mainly depends on TNM and BCLC staging, but they cannot accurately reflect the true characteristics of the tumor and the prognostic risk. Clinically, there are not enough sensitive and specific in...

Images